BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol 2021:S0168-8278(21)00343-3. [PMID: 34090928 DOI: 10.1016/j.jhep.2021.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Morieri ML, Targher G, Lapolla A, D'Ambrosio M, Tadiotto F, Rigato M, Frison V, Paccagnella A, Simioni N, Avogaro A, Fadini GP. Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. Nutr Metab Cardiovasc Dis 2021;31:3474-83. [PMID: 34629258 DOI: 10.1016/j.numecd.2021.08.049] [Reference Citation Analysis]
2 Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2021:S0168-8278(21)02026-2. [PMID: 34508791 DOI: 10.1016/j.jhep.2021.08.028] [Reference Citation Analysis]
3 Zhou YJ, Zheng MH. Editorial: an elastography-based two-step approach to detect NAFLD with compensated advanced chronic liver disease-authors' reply. Aliment Pharmacol Ther 2021;54:517-8. [PMID: 34331809 DOI: 10.1111/apt.16528] [Reference Citation Analysis]
4 Lima RVC, Stefano JT, Malta FM, Pinho JRR, Carrilho FJ, Arrese M, Oliveira CP. Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients. Biomedicines 2021;9:1751. [PMID: 34944567 DOI: 10.3390/biomedicines9121751] [Reference Citation Analysis]
5 Loosen SH, Kostev K, Keitel V, Tacke F, Roderburg C, Luedde T. An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD. J Hepatol 2021:S0168-8278(21)02028-6. [PMID: 34520785 DOI: 10.1016/j.jhep.2021.08.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]